RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY26 results · Jul–Sep 2025
RPG Life Sciences reported revenue from operations of ₹181.68 crore (up 5.5% from Q2 FY25) and net profit of ₹36.85 crore (up 777.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 181.68 | 172.21 | +5.5% | 168.92 | +7.6% |
| Other income | 4.54 | 1.94 | +134.0% | 5.23 | −13.2% |
| Total income | 186.22 | 174.15 | +6.9% | 174.15 | +6.9% |
| Profit before tax | 49.45 | 15.09 | +227.7% | 35.43 | +39.6% |
| Net profit for the period | 36.85 | 4.20 | +777.4% | 26.29 | +40.2% |
| EPS, basic (₹) | 22.28 | 2.54 | +777.2% | 15.90 | +40.1% |
| Net margin (%) | 20.3 | 2.4 | 15.6 |
Standalone
- Filed with BSE
- 17 Oct 2025, 19:44 IST
- Board meeting
- 17 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE